In this episode of the Gaining Health podcast, host Karli Burridge gives us Part 2 of her updates from this summer!She summarizes the findings of the cardiovascular outcome trials of semaglutide 2.4mg (Wegovy) in participants with obesity, which (spoiler alert) reduced the incidence of major adverse cardiovascular events  (MACE) by 20%!!! Read the Novo Nordisk company announcement HEREShe also reviews the recent study on the effects of semaglutide 2.4 mg in patients with obesity and heart failure with preserved ejection fraction (read the article HERE) , and reviews the news release from Eli Lilly on the SURMOUNT 3 and 4 clinical trials on tirzepatide for the treatment of overweight and obesity. While some of these studies have yet to be published by peer-reviewed journals, they do offer great hope for patients living with obesity and may offer us safe and effective tools to reduce the #1 cause of mortality: cardiovascular disease. Support the showThe Gaining Health Podcast will release a new episode every Wednesday, alternating between interviews with experts and "What's Up Wednesday" scientific updates.For a roadmap for developing an obesity program, editable forms and templates, patient education materials, and more, check out Gaining Health If you are loving this podcast, please consider supporting us on Patreon